Attitudes toward pharmacological cognitive enhancement-a review

Frontiers in Systems Neuroscience

Volumn 8, Issue 1 APR, 2014, Pages

  Schelle, Kimberly J ^a   Faulmüller, Nadira ^b,c   Caviola, Lucius ^b   Hewstone, Miles ^b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Authenticity; Brain function augmentation; Coercion; Cognitive enhancement; Fairness; Medical safety; Neuroenhancement; Smart drugs

Indexed keywords

ATTITUDE; BRAIN FUNCTION; COGNITION; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HEALTH HAZARD; HUMAN; INTERVIEW; MENTAL PERFORMANCE; PUBLIC HEALTH PROBLEM; QUESTIONNAIRE; REVIEW;

EID: 84898880558     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2014.00053     Document Type: Review

References (83)

1. Aikins, R. D. (2011). Academic performance enhancement: a qualitative study of the perceptions and habits of prescription stimulant-using college students. J. Coll. Stud. Dev. 52, 560-576. doi: 10. 1353/csd. 2011. 0064.
2. Asscher, E. C. A., and Schermer, M. (2013). Wish-fulfilling medicine in practice: the opinions and arguments of lay people. J. Med. Ethics. doi: 10. 1136/medethics-2013-101480. [Epub ahead of print].
3. Bachman, J. G., Johnson, L. D., and O'Malley, P. M. (1998). Explaining recent increases in students' marijuana use: impacts of perceived risks and disapproval, 1976 through 1996. Am. J. Public Health 88, 887-892. doi: 10. 2105/AJPH. 88. 6. 887.
4. Ball, N., and Wolbring, G. (2014). Cognitive enhancement: perceptions among parents of children with disabilities. Neuroethics 1-20. doi: 10. 1007/s12152-014-9201-8. [Epub ahead of print].
5. Banjo, O. C., Nadler, R., and Reiner, P. B. (2010). Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS ONE 5: e14322. doi: 10. 1371/journal. pone. 0014322.
6. Banks, S., Scully, J. L., and Shakespeare, T. (2006). Ordinary ethics: lay people's deliberations on social sex selection. New Genet. Soc. 25, 289-303. doi: 10. 1080/14636770601032890.
7. Bavarian, N., Flay, B. R., Ketcham, P. L., and Smit, E. (2013). Illicit use of prescription stimulants in a college student sample: a theory-guided analysis. Drug Alcohol Depend. 132, 665-673. doi: 10. 1016/j. drugalcdep. 2013. 04. 024.
8. Bell, S., Partridge, B., Lucke, J., and Hall, W. (2013). Australian university students' attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics 6, 197-205. doi: 10. 1007/s12152-012-9153-9.
9. Bergström, L. S., and Lynöe, N. (2008). Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Scand. J. Public Health. 36, 532-537. doi: 10. 1177/1403494807087558.
10. Bossaer, J. B., Gray, J. A., Miller, S. E., Enck, G., Gaddipati, V. C., and Enck, R. E. (2013). The use and misuse of prescription stimulants as "cognitive enhancers" by students at one academic health sciences center. Acad. Med. 88, 967-971. doi: 10. 1097/Acm. 0b013e318294fc7b.
11. Bostrom, N., and Ord, T. (2006). The reversal test: eliminating status quo bias in applied ethics. Ethics 116, 656-679. doi: 10. 1086/505233.
12. Bostrom, N., and Sandberg, A. (2009). Cognitive enhancement: methods, ethics, regulatory challenges. Sci. Eng. Ethics 15, 311-341. doi: 10. 1007/s11948-009-9142-5.
13. Cabriales, J. A., Cooper, T. V., and Taylor, T. (2013). Prescription drug misuse, illicit drug use, and their potential risk and protective correlates in a Hispanic college student sample. Exp. Clin. Psychopharmacol. 21, 235-244. doi: 10. 1037/a0031973.
14. Cozby, P. C. (2009). Methods in Behavioral Research. New York, NY: McGraw-Hill.
15. Daniels, N. (2000). Normal functioning and the treatment-enhancement distinction. Camb. Q. Healthc. Ethics 9, 309-322. doi: 10. 1017/S0963180100903037.
16. Delaney, J. J., and Martin, D. P. (2011). The role of physician opinion in human enhancement. Am. J. Bioeth. 11, 19-20. doi: 10. 1080/15265161. 2010. 534537.
17. Desantis, A. D., and Hane, A. C. (2010). "Adderall is definitely not a drug": justifications for the illegal use of ADHD stimulants. Subst. Use Misuse 45, 31-46. doi: 10. 3109/10826080902858334.
18. Dodge, T., Williams, K. J., Marzell, M., and Turrisi, R. (2012). Judging cheaters: is substance misuse viewed similarly in the athletic and academic domains? Psychol. Addict. Behav. 26, 678-682. doi: 10. 1037/A0027872.
19. Dubljevic, V. (2013). Cognitive enhancement, rational choice and justification. Neuroethics 6, 179-187. doi: 10. 1007/s12152-012-9173-5.
20. Dubljević, V., Sattler, S., and Racine, E. (2013). Cognitive enhancement and academic misconduct: a study exploring their frequency and relationship. Ethics Behav. doi: 10. 1080/10508422. 2013. 869747. [Epub ahead of print].
21. Eickenhorst, P., Vitzthum, K., Klapp, B. F., Groneberg, D., and Mache, S. (2012). Neuroenhancement among German university students: motives, expectations, and relationship with psychoactive lifestyle drugs. J. Psychoactive Drugs 44, 418-427. doi: 10. 1080/02791072. 2012. 736845.
22. European Citizens' Panel. (2006). Meeting of Minds, European Citizens' Deliberation on Brain Science. Available online at: http://www. kbs-frb. be/otheractivity. aspx?id=193934&langtype=1033 (Accessed January 15, 2014).
23. Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., et al. (2004). Neurocognitive enhancement: what can we do and what should we do? Nat. Rev. Neurosci. 5, 421-425. doi: 10. 1038/nrn1390.
24. Farah, M. J., Smith, M. E., Ilieva, I., and Hamilton, R. H. (2014). Cognitive enhancement. WIREs Cogn Sci. 5, 95-103. doi: 10. 1002/wcs. 1250.
25. Faulmüller, N., Maslen, H., and Santoni de Sio, F. (2013). The indirect psychological costs of cognitive enhancement. Am. J. Bioeth. 13, 45-47. doi: 10. 1080/15265161. 2013. 794880.
26. Festinger, L. (1957). A Theory of Cognitive Dissonance. Stanford, CA: Stanford University Press.
27. Finger, G., da Silva, E. R., and Falavigna, A. (2013). Use of methylphenidate among medical students: a systematic review. Rev. Assoc. Med. Bras. 59, 285-289. doi: 10. 1016/J. Ramb. 2012. 10. 007.
28. Fitz, N. S., Nadler, R., Manogaran, P., Chong, E. W. J., and Reiner, P. B. (2013). Public attitudes toward cognitive enhancement. Neuroethics. doi: 10. 1007/s12152-013-9190-z.
29. Forlini, C., and Racine, E. (2009). Autonomy and coercion in academic "Cognitive Enhancement" using methylphenidate: perspectives of key stakeholders. Neuroethics 2, 163-177. doi: 10. 1007/s12152-009-9043-y.
30. Forlini, C., and Racine, E. (2012a). Added stakeholders, added value(s) to the cognitive enhancement debate: are academic discourse and professional policies sidestepping values of stakeholders? AJOB Prim. Res. 3, 33-47. doi: 10. 1080/21507716. 2011. 645116.
31. Forlini, C., and Racine, E. (2012b). Stakeholder perspectives and reactions to "academic" cognitive enhancement: unsuspected meaning of ambivalence and analogies. Public Underst. Sci. 21, 606-625. doi: 10. 1177/0963662510385062.
32. Franke, A. G., Bagusat, C., Dietz, P., Hoffmann, I., Simon, P., Ulrich, R., et al. (2013). Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med. 11: 102. doi: 10. 1186/1741-7015-11-102.
33. Franke, A. G., Bonertz, C., Christmann, M., Engeser, S., and Lieb, K. (2012a). Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study. AJOB Prim. Res. 3, 48-57. doi: 10. 1080/21507716. 2011. 608411.
34. Franke, A. G., Lieb, K., and Hildt, E. (2012b). What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS ONE 7: e40047. doi: 10. 1371/journal. pone. 0040047.
35. Franke, A. G., Papenburg, C., Schotten, E., Reiner, P. B., and Lieb, K. (2014). Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany. BMC Fam. Pract. 15: 3. doi: 10. 1186/1471-2296-15-3.
36. Goodman, R. (2010). Cognitive enhancement, cheating, and accomplishment. Kennedy Inst. Ethics J. 20, 145-160. doi: 10. 1353/ken. 0. 0309.
37. Habermas, J. (2003). The Future of Human Nature. Cambridge: Polity Press.
38. Hotze, T. D., Shah, K., Anderson, E. E., and Wynia, M. K. (2011). "Doctor, would you prescribe a pill to help me...?" a national survey of physicians on using medicine for human enhancement. Am. J. Bioeth. 11, 3-13. doi: 10. 1080/15265161. 2011. 534957.
39. Husain, M., and Mehta, M. A. (2011). Cognitive enhancement by drugs in health and disease. Trends Cogn. Sci. 15, 28-36. doi: 10. 1016/j. tics. 2010. 11. 002.
40. Hyman, S. E. (2011). Cognitive enhancement: promises and perils. Neuron 69, 595-598. doi: 10. 1016/j. neuron. 2011. 02. 012.
41. Ilieva, I., Boland, J., and Farah, M. J. (2013). Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology 64, 496-505. doi: 10. 1016/j. neuropharm. 2012. 07. 021.
42. Judson, R., and Langdon, S. W. (2009). Illicit use of prescription stimulants among college students: prescription status, motives, theory of planned behaviour, knowledge and self-diagnostic tendencies. Psychol. Health Med. 14, 97-104. doi: 10. 1080/13548500802126723.
43. Kahneman, D., and Tversky, A. (2000). Choices, Values, and Frames. New York, NY: Cambridge University Press.
44. King, S., Griffin, S., Hodges, Z., Weatherly, H., Asseburg, C., Richardson, G., et al. (2006). A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol. Assess 10, iii-iv, xiii-146.
45. Kociancic, T., Reed, M. D., and Findling, R. L. (2004). Evaluation of risks associated with short-and long-term psychostimulant therapy for treatment of ADHD in children. Expert Opin. Drug Saf. 3, 93-100. doi: 10. 1517/eods. 3. 2. 93. 27337.
46. Kroutil, L. A., Van Brunt, D. L., Herman-Stahl, M. A., Heller, D. C., Bray, R. M., and Penne, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 84, 135-143. doi: 10. 1016/j. drugalcdep. 2005. 12. 011.
47. Kudlow, P. A., Treurnicht Naylor, K., Xie, B., and McIntyre, R. S. (2013). Cognitive enhancement in Canadian medical students. J. Psychoactive Drugs45, 360-365. doi: 10. 1080/02791072. 2013. 825033.
48. Maher, B. (2008). Poll results: look who's doping. Nature 452, 674-675. doi: 10. 1038/452674a.
49. Maier, L. J., Liechti, M. E., Herzig, F., and Schaub, M. P. (2013). To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS ONE 8: e77967. doi: 10. 1371/journal. pone. 0077967.
50. Maslen, H., Santoni de Sio, F., and Faulmüller, N. (in press). "With cognitive enhancement comes great responsibility?, " in Responsible Innovation. Vol. 2, eds B. J. Koops et al. (Dordrecht: Springer).
51. Mazanov, J., Dunn, M., Connor, J., and Fielding, M. L. (2013). Substance use to enhance academic performance among Australian university students. Perform. Enhance. Health 2, 110-118. doi: 10. 1016/j. peh. 2013. 08. 017.
52. McCabe, S. E., Knight, J. R., Teter, C. J., and Wechsler, H. (2005). Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 99, 96-106. doi: 10. 1111/j. 1360-0443. 2004. 00944. x.
53. Ott, R., and Biller-Andorno, N. (2013). Neuroenhancement among Swiss students-a comparison of users and non-users. Pharmacopsychiatry 47, 22-28. doi: 10. 1055/s-0033-1358682.
54. Ott, R., Lenk, C., Miller, N., Neuhaus Buhler, R., and Biller-Andorno, N. (2012). Neuroenhancement-perspectives of Swiss psychiatrists and general practitioners. Swiss Med. Wkly. 142, w13707. doi: 10. 4414/smw. 2012. 13707.
55. Parens, E. (1998). Enhancing Human Traits: Ethical and Social Implications. Washington, DC: Georgetown University Press.
56. Partridge, B., Bell, S., Lucke, J., and Hall, W. (2013). Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. Drug Alcohol Rev. 32, 295-302. doi: 10. 1111/dar. 12005.
57. Partridge, B., Lucke, J., and Hall, W. (2012). A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. AJOB Prim. Res. 3, 81-86. doi: 10. 1080/21507716. 2012. 720639.
58. Partridge, B., Underwood, M., Lucke, J., Bartlett, H., and Hall, W. (2009). Ethical concerns in the community about technologies to extend human life span. Am. J. Bioeth. 9, 68-76. doi: 10. 1080/15265160903318368.
59. President's Council on Bioethics. (2003). Beyond Therapy. Biotechnology and the Pursuit of Happiness. Available online at: https://bioethicsarchive. georgetown. edu/pcbe/reports/beyondtherapy/index. html (Accessed March 31, 2014).
60. Rawls, J. A. (1971). A Theory of Justice. Cambridge, MA: Harvard University Press.
61. Rawls, J. A. (1985). Justice as fairness: political not metaphysical. Philos. Public Aff. 14, 223-251.
62. Repantis, D., Schlattmann, P., Laisney, O., and Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res. 62, 187-206. doi: 10. 1016/j. phrs. 2010. 04. 002.
63. Riis, J., Simmons, J. P., and Goodwin, G. P. (2008). Preferences for enhancement pharmaceuticals: the reluctance to enhance fundamental traits. J. Cons. Res. 35. doi: 10. 1086/588746.
64. Sabini, J., and Monterosso, J. (2005). Judgments of the fairness of using performance enhancing drugs. Ethics Behav. 15, 81-94. doi: 10. 1207/s15327019eb1501_6.
65. Santoni de Sio, F., Faulmüller, N., Savulescu, J., and Vincent, N. A. (in press). "Moving beyond responsibility-shifting, authenticity, and cheating, towards a nature-of-activities approach, " in Cognitive Enhancement: Ethical and Policy Implications in International Perspectives, eds F. Jotterand, and V. Dubljevic (Oxford: Oxford University Press).
66. Sarewitz, D. (2010). World view: not by experts alone. Nature 466, 688. doi: 10. 1038/466688a.
67. Sattler, S., Forlini, C., Racine, E., and Sauer, C. (2013a). Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement. PLoS ONE 8: e71452. doi: 10. 1371/journal. pone. 0071452.
68. Sattler, S., Mehlkop, G., Graeff, P., and Sauer, C. (2014). Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics. Subst. Abuse Treat. Prev. Policy 9, 1-14. doi: 10. 1186/1747-597X-9-8.
69. Sattler, S., Sauer, C., Mehlkop, G., and Graeff, P. (2013b). The rationale for consuming cognitive enhancement drugs in university students and teachers. PLoS ONE 8: e68821. doi: 10. 1371/journal. pone. 0068821.
70. Sattler, W., and Wiegel, C. (2013). Cognitive test anxiety and cognitive enhancement: the influence of students' worries on their use of performance-enhancing drugs. Subst. Use Misuse 48, 220-232. doi: 10. 3109/10826084. 2012. 751426.
71. Schaefer, G. O., Kahane, G., and Savulescu, J. (2013). Autonomy and enhancement. Neuroethics. doi: 10. 1007/s12152-013-9189-5. [Epub ahead of print].
72. Schermer, M. (2008). Enhancements, easy shortcuts, and the richness of human activities. Bioethics 22, 355-363. doi: 10. 1111/j. 1467-8519. 2008. 00657. x.
73. Schermer, M., Bolt, I., De Jongh, R., and Olivier, B. (2009). The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2, 75-87. doi: 10. 1007/s12152-009-9032-1.
74. Scheske, C., and Schnall, S. (2012). The ethics of 'smart drugs': moral judgments about healthy people's use of cognitive-enhancing drugs. Basic Appl. Soc. Psych. 34, 508-515. doi: 10. 1080/01973533. 2012. 711692.
75. Schicktanz, S., Schweda, M., and Wynne, B. (2012). The ethics of 'public understanding of ethics'-why and how bioethics expertise should include public and patients' voices. Med. Health Care Philos. 15, 129-139. doi: 10. 1007/s11019-011-9321-4.
76. Schildmann, J., Beranek, R., and Roser, P. (2013). "Prevalence and attitudes to neurenhancement among students., results of a survey at the UAMR Universities" in Conference Presentation (Bochum: Ruhr University Bochum, Bochum).
77. Schoomaker, E. B. (2007). Military medical research on cognitive performance: the warfighter's competitive edge. Aviat. Space Environ. Med. 78, B4-B6.
78. Schuijff, M., and Brom, F. W. A. (2013). "The dynamics of citizen deliberation regarding human enhancement in the Netherlands, " in Beyond Therapy v. Enhancement? Multidisciplinary Analysis of a Heated Debate, ed F. Lucivero and A. Vedder (Pisa: Pisa University Press), 143-161.
79. Smith, M. E., and Farah, M. J. (2011). Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull. 137, 717-741. doi: 10. 1037/a0023825.
80. Sweeney, S. (2010). The use of prescription drugs for academic performance enhancement in college aged students. Social Work Theses Paper 48.
81. Teter, C. J., McCabe, S. E., Cranford, J. A., Boyd, C. J., and Guthrie, S. K. (2005). Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am. Coll. Health. 53, 253-262. doi: 10. 3200/Jach. 53. 6. 253-262.
82. Van Der Schaaf, M. E., Fallon, S. J., Ter Huurne, N., Buitelaar, J., and Cools, R. (2013). Working memory capacity predicts effects of methylphenidate on reversal learning. Neuropsychopharmacology 38, 2011-2018. doi: 10. 1038/npp. 2013. 100.
83. Warren, O. J., Leff, D. R., Athanasiou, T., Kennard, C., and Darzi, A. (2009). The neurocognitive enhancement of surgeons: an ethical perspective. J. Surg. Res. 152, 167-172. doi: 10. 1016/j. jss. 2007. 12. 761.